New IgA nephropathy drug shows early promise in small trial
NCT ID NCT07634744
First seen Jun 14, 2026 · Last updated Jun 14, 2026
Summary
This study tested a new drug called XH-S003 in 25 adults with IgA nephropathy, a kidney disease. The goal was to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage, after 90 days. Participants had to have a kidney biopsy confirming the disease. The study did not aim to cure the disease, but to control it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.